Veryan Medical announces multimillion-euro investment in Galway operation

Galway, 06 April 2021 Veryan has announced a multimillion-euro investment at its Galway facility that will contribute to the further expansion and diversification of Veryan’s product portfolio beyond the BioMimics 3D Swirling Flow stent, marketed in Europe and USA to improve blood flow through arteries in the leg.

Download pdf – PRESS RELEASE VERYAN OTSUKA INVESTMENT GALWAY FINAL 06 April 2021 (1)

BioMimics 3D Vascular Stent System has FDA and CE Mark approval.
BioMimics 3D & Swirling Flow Stent are registered trademarks of Veryan Medical Limited.
Veryan Medical Limited is a member of the Otsuka Medical Devices group of companies.
CAUTION: Federal law restricts this device to sale by or on the order of a physician.

PAM 14 Version 3.0